Annual report pursuant to Section 13 and 15(d)

Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)

v3.24.0.1
Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Agreements    
Short-term royalty receivable, Balance as of beginning of period $ 2,366  
Short-term royalty receivable, Balance as of end of period 14,215 $ 2,366
Long-term royalty receivable, Balance as of beginning of period 63,683 69,075
Long-term royalty receivable, Balance as of end of period 57,952 63,683
Affitech    
Agreements    
Receipt of royalty and commercial payments, Short-Term (7,284)  
Reclassification to short-term royalty and commercial payment receivables, Short-Term 17,109 2,366
Receipt of royalty and commercial payments, Long-Term   (526)
Reclassification to short-term royalty and commercial payment receivables, Long-Term (17,109) (2,366)
Recognition of contingent consideration, Long-Term 6,000  
Aptevo    
Agreements    
Reclassification to short-term royalty and commercial payment receivables, Short-Term 2,024  
Acquisition of royalty and commercial payment receivables, Long-Term 9,650  
Receipt of royalty and commercial payments, Long-Term (1,673)  
Reclassification to short-term royalty and commercial payment receivables, Long-Term (2,024)  
LadRx    
Agreements    
Acquisition of royalty and commercial payment receivables, Long-Term 6,000  
Bioasis    
Agreements    
Impairment of royalty and commercial payment receivables, Long-Term (1,575)  
Viracta    
Agreements    
Receipt of royalty and commercial payments, Long-Term $ (5,000)  
Kuros    
Agreements    
Receipt of royalty and commercial payments, Long-Term   $ (2,500)